Sign in

BRTX on Nasdaq

BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is an American misc health and allied services company based in Melville.2 Its shares trade on Nasdaq under the symbol BRTX.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with MANGOCEUTICALS, INC., NewGenIvf Group Ltd or Charming Medical Ltd, or pick any stock.

  • TickerBRTX on Nasdaq2
  • IndustryServices-Misc Health & Allied Services, NEC2
  • HeadquartersJupiter, United States2
  • Incorporated inNV3
  • Business address40 Marcus Drive, Suite One, Melville, Ny3
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300I1PJXVT7ISIV912
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O United Corporate Services, Inc., 89703 Carson City, United States2

See how the biggest companies compare on our leaderboards

Patents related to the ThermoStem Program have been issued in the United States and other jurisdictions.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

93.4%Gross margin5
-4350.1%Operating margin5
-3959.4%Net margin5
-10.3%Revenue growth, 20255
-3992.2%Return on equity5
-$10.9MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 83% of the revenue BioRestorative Therapies, Inc. broke down this way in fiscal 2025.

  1. Product$300.0K583%up 0% from 2024
  2. Royalty$59.7K517%down 41% from 2024
Products and services by year
Products and services20242025
Product$300.0K$300.0K
Royalty$101.0K$59.7K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue0¢$23.8K
  • Research and development100¢$10.1M

Out of $359.7K in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$359.7K in 2025+177% since 2019
0$200.0K$400.0K$600.0K2019: $130.0K$130.0K20192020: $77.0K$77.0K2020−41%2021: $46.0K$46.0K2021−40%2022: $119.8K$119.8K2022+160%2023: $145.8K$145.8K2023+22%2024: $401.0K$401.0K2024+175%2025: $359.7K$359.7K2025−10%
Gross profit105$335.9K in 2025+130% since 2023
0$100.0K$200.0K$300.0K$400.0K2023: $145.8K$145.8K20232024: $372.9K$372.9K2024+156%2025: $335.9K$335.9K2025−10%
Operating income6789105-$15.6M in 2025+86% since 2019
-$30.0M-$20.0M-$10.0M02019: -$8.4M-$8.4M20192020: -$2.8M-$2.8M2020−67%2021: -$26.3M-$26.3M2021+856%2022: -$19.0M-$19.0M2022−28%2023: -$15.2M-$15.2M2023−20%2024: -$11.6M-$11.6M2024−24%2025: -$15.6M-$15.6M2025+35%
Net income6789105-$14.2M in 2025−3% since 2019
-$60.0M-$40.0M-$20.0M02019: -$14.6M-$14.6M20192020: -$11.3M-$11.3M2020−23%2021: -$44.3M-$44.3M2021+293%2022: -$13.2M-$13.2M2022−70%2023: -$10.4M-$10.4M2023−21%2024: -$9.0M-$9.0M2024−14%2025: -$14.2M-$14.2M2025+59%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenues$359.7K$401.0K
Cost of goods sold$23.8K$28.1K
Gross profit$335.9K$372.9K
Research and development$10.1M$6.7M
General and administrative$5.9M$5.2M
Total Operating Expenses$16.0M$11.9M
Loss From Operations-$15.6M-$11.6M
Interest income, net$266.2K$616.1K
Other income$17.4K$150.8K
Gain on exchange of warrants$1.7M
Change in fair value of warrant liabilities$1.1M$97.2K
Total Other Income$1.4M$2.6M
Net Loss-$14.2M-$9.0M
Net Loss Per Share - Basic-$1.58-$1.16
Net Loss Per Share - Diluted-$1.58-$1.16
Weighted Average Common Shares Outstanding - Basic9.0M shares7.8M shares
Weighted Average Common Shares Outstanding - Diluted9.0M shares7.8M shares

Compare BioRestorative Therapies, Inc. with another company

Corporate structure

BioRestorative Therapies, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BioRestorative Therapies, Inc.

  • Alta Partners LLC Filed SCHEDULE 13G/A on BioRestorative Therapies, Inc., latest Aug 3, 2026 (2 filings since Feb 13, 2026)
  • Auctus Fund Management LLC Filed SCHEDULE 13G/A on BioRestorative Therapies, Inc., latest May 15, 2026 (8 filings since Jul 14, 2022)
  • Todd Hale Morrison Filed SCHEDULE 13G/A on BioRestorative Therapies, Inc., latest Feb 23, 2026 (7 filings since Jun 21, 2024)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G on BioRestorative Therapies, Inc., latest Feb 18, 2026
  • Francisco Silva Filed SCHEDULE 13D/A on BioRestorative Therapies, Inc., latest Feb 19, 2025 (3 filings since Feb 17, 2023)
  • Lance Alstodt Filed SCHEDULE 13D/A on BioRestorative Therapies, Inc., latest Feb 19, 2025 (3 filings since Feb 17, 2023)
  • Dale Broadrick Filed SC 13D/A on BioRestorative Therapies, Inc., latest Mar 6, 2024 (4 filings since Mar 29, 2022)
  • Hudson Bay Capital Management LP Filed SC 13G/A on BioRestorative Therapies, Inc., latest Feb 7, 2023 (2 filings since Feb 2, 2022)
  • Altium Capital Management LLC Filed SC 13G/A on BioRestorative Therapies, Inc., latest Feb 14, 2022 (2 filings since Nov 16, 2021)
  • SABBY MANAGEMENT, LLC Filed SC 13G/A on BioRestorative Therapies, Inc., latest Jan 4, 2022 (2 filings since Nov 9, 2021)
  • BioRestorative Therapies, Inc. Jupiter, Florida, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BioRestorative Therapies, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.6M5 Dec 31, 2025$1.5M5 Dec 31, 2024+7.9%
Accumulated depreciation$1.2M5 Dec 31, 2025$1.1M5 Dec 31, 2024+10.8%
Property and equipment, net$358.8K5 Dec 31, 2025$362.9K5 Dec 31, 2024−1.1%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.5M5 Dec 31, 2025$547.9K5 Dec 31, 2024+175.8%
Marketable securities, current$1.4M5 Dec 31, 2025$10.2M5 Dec 31, 2024−85.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$534.2K5 Dec 31, 2025$623.9K5 Dec 31, 2024−14.4%
Finite-lived intangibles, net$534.2K5 Dec 31, 2025$448.7K10 Dec 31, 2024+19.0%

Properties, in its own words

Our principal executive offices and laboratory are located at 40 Marcus Drive, Suite One, Melville, New York. We occupy 6,800 square feet of space at the premises pursuant to a lease that expired in December 2024. The lease provided for a current annual base rental of $173,060. We currently occupy the premises on a month-to-month basis at a monthly rental of $14,422 and are negotiating an extension of the term of the lease. Our premises are suitable and adequate for our current operations.

Item 2 of the 10-K filed Mar 26, 2026.4

Leadership

Who has led BioRestorative Therapies, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Lance Alstodt2020–now

President

  1. Lance Alstodt2020–now

Chief financial officer

  1. Robert Eugene Kristal2021–now
201520202025
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Director, Executive OfficerFrancisco Silva named Oct 9, 202529
  • DirectorNickolay V Kukekov named Oct 9, 202529
  • DirectorPatrick F Williams named Oct 9, 202529

Former names

  • Stem Cell Assurance, Inc.Nov 16, 2010 to Aug 16, 20113

Timeline

  1. Oct 9, 20268-K Executive or director change30
  2. Sep 11, 20268-K Executive or director change31
  3. Sep 10, 20268-K Change of auditor; Other events32
  4. Sep 2, 20268-K Change of auditor; Executive or director change33
  5. Sep 2, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Regulation FD disclosure34
  6. Aug 25, 20268-K Listing notice or transfer35
  7. Aug 14, 20268-K Other events36
  8. Jul 16, 20268-K Executive or director change37
  9. Jun 12, 20268-K Entered a material agreement; Executive or director change38
  10. Jun 12, 20268-K Executive or director change39
  11. May 29, 20268-K Executive or director change; Shareholder vote40
  12. May 1, 20268-K Executive or director change41
  13. Nov 24, 2020New chief executive Lance Alstodt becomes CEO14

Calendar

Coming up

  1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($7.60) a share, on Nov 12, 2025.42

When it reported results

  1. Nov 12, 2025Reported quarterly or annual results43
  2. Aug 12, 2025Reported quarterly or annual results44
  3. May 14, 2025Reported quarterly or annual results45
  4. Mar 27, 2025Reported quarterly or annual results46
  5. Nov 13, 2024Reported quarterly or annual results47
  6. Aug 13, 2024Reported quarterly or annual results48
  7. Aug 6, 2024Reported quarterly or annual results49

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

290 filings to the SEC since October 2021: 7 annual reports, 14 quarterly reports, 49 major events, 120 insider forms, 34 large holders, 1 private raises, 65 other. The latest 20:

  1. Oct 9, 20268-K CURRENT REPORT EDGAR
  2. Sep 11, 20268-K CURRENT REPORT EDGAR
  3. Sep 10, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  4. Sep 2, 20268-K CURRENT REPORT EDGAR
  5. Sep 2, 20268-K CURRENT REPORT EDGAR
  6. Aug 25, 20268-K CURRENT REPORT EDGAR
  7. Aug 14, 2026NT 10-Q EDGAR
  8. Aug 14, 20268-K EDGAR
  9. Aug 3, 2026SCHEDULE 13G/A EDGAR
  10. Jul 30, 20263 EDGAR
  11. Jul 24, 20263 PRIMARY DOCUMENT EDGAR
  12. Jul 16, 20268-K EDGAR
  13. Jun 18, 20263 EDGAR
  14. Jun 18, 20263 EDGAR
  15. Jun 17, 20263 EDGAR
  16. Jun 12, 20268-K CURRENT REPORT FILING EDGAR
  17. Jun 12, 20268-K CURRENT REPORT FILING EDGAR
  18. May 29, 20268-K FORM 8-K DATED MARCH 26, 2026 EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. May 14, 202610-Q EDGAR

The 290 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

91 open-market trades by officers, directors and large owners since October 2021: 86 buys and 5 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 28, 2024Broadrick Dale10% ownerSale1,112$1.58$1.8KForm 4
Apr 9, 2024Silva FranciscoVP of Research and DevelopmentBuy6,600$1.25$8.2KForm 4
Apr 8, 2024Silva FranciscoVP of Research and DevelopmentBuy1,708$1.16$2.0KForm 4
Feb 9, 2024Broadrick Dale10% ownerBuy86,041$1.32$113.6KForm 4
Feb 8, 2024Broadrick Dale10% ownerBuy73,959$1.25$92.4KForm 4
Feb 8, 2024Broadrick Dale10% ownerBuy83,626$1.34$112.1KForm 4
Feb 7, 2024Broadrick Dale10% ownerBuy36,374$1.38$50.2KForm 4
Dec 1, 2023Broadrick Dale10% ownerSale250$1.88$470Form 4
Nov 27, 2023Broadrick Dale10% ownerSale278$1.89$525Form 4
Sep 15, 2023Broadrick Dale10% ownerBuy10,000$1.66$16.6KForm 4
Sep 15, 2023ALSTODT LANCEPresident, CEO, COBBuy2,200$1.70$3.7KForm 4
Sep 14, 2023Broadrick Dale10% ownerBuy10,000$1.54$15.4KForm 4
Sep 13, 2023ALSTODT LANCEPresident, CEO, COBBuy800$1.53$1.2KForm 4
Sep 7, 2023Broadrick Dale10% ownerBuy2,000$1.86$3.7KForm 4
Sep 6, 2023ALSTODT LANCEPresident, CEO, COBBuy2,887$1.96$5.7KForm 4
Aug 31, 2023Silva FranciscoVP of Research and DevelopmentBuy4,954$2.22$11.0KForm 4
Jul 28, 2023Broadrick Dale10% ownerBuy500$2.89$1.4KForm 4
Jul 27, 2023Broadrick Dale10% ownerBuy1,000$2.80$2.8KForm 4
Jul 25, 2023ALSTODT LANCEPresident, CEO, COBBuy4,200$2.44$10.2KForm 4
Mar 31, 2023Silva FranciscoVP of Research and DevelopmentBuy747$3.56$2.7KForm 4

All 91 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Oct 8, 2025Raised $1.4 million in a private offering of equity Form D: 16 investors so far Form D

SEC filer profile

How BioRestorative Therapies, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBioRestorative Therapies, Inc.1
  • CIK0001505497
  • Employer ID (EIN)30-13410244
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inNevada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)8090 Services-Misc Health & Allied Services, NEC1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address40 Marcus Drive, Suite One, Melville, NY1
  • Phone(631) 760-81001
  • Shares outstanding25,478,170 as of May 14, 202613
  • Public float$11.2M as of Jun 30, 20254
  • AuditorCBIZ CPAs P.C., Marlton, New Jersey PCAOB ID 199; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceNov 16, 20101
  • Filings754 in all: 4 (261), 8-K (172), 10-Q (45), 3 (27), CORRESP (19), DEF 14A (19), SC 13D/A (19), 10-K (15)1
    All 46 form types

    PRE 14A (12), SCHEDULE 13G/A (12), S-8 (11), UPLOAD (11), S-1/A (10), SC 13G (10), EFFECT (9), SC 13G/A (8), 424B5 (7), S-1 (7), SC 13D (7), NT 10-Q (6), D (5), D/A (5), NT 10-K (5), 424B3 (4), 8-K/A (4), POS AM (4), 10-12G/A (3), 10-Q/A (3), 4/A (3), 424B4 (3), DEFA14A (3), FWP (3), SCHEDULE 13G (3), 10-K/A (2), 8-A12B (2), CT ORDER (2), RW (2), S-3 (2), SCHEDULE 13D/A (2), 10-12G (1), 424B2 (1), CERT (1), DRS (1), PRER14A (1), S-1MEF (1), S-3/A (1)

  • Latest filingsAnnual report (10-K) Mar 26, 2026
    Quarterly report (10-Q) May 14, 2026
    Proxy statement (DEF 14A) Apr 13, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock $0.0001 par valueBRTXNasdaq

From the cover page of the 10-K filed Mar 26, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks BioRestorative Therapies, Inc. names in Item 1A of its 10-K filed Mar 26, 2026: 55 risks under these headings, as written.4

  • Risks Related to Our Business Generally
  • Risks Related to Our Cell Therapy Product Development Efforts
  • Risks Related to Our Intellectual Property
  • Risks Related to Government Regulation
  • Risks Related to Our Common Stock
  • Risks Associated with Our Nasdaq Listing
  • We have a limited operating history; we have incurred substantial losses since inception; we expect to continue to incur losses for the near term; there is substantial doubt about our ability to continue as a going concern within the next twelve months from the date of this filing; the report of our independent registered public accounting firm contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern.
  • We will need to obtain a significant amount of financing to complete our clinical trials and implement our business plan.
  • Our business strategy is high risk.
  • We will need to enter into agreements in order to implement our business strategy.
  • We depend on our executive officers and on our ability to attract and retain additional qualified personnel.
  • In the event that we are unable to utilize our current premises and need to relocate, we will be required to comply with regulatory requirements as to the operation of our laboratory, which could have had a material adverse effect on the conduct of our clinical trials and on our business.
The other 49 risks
  • Our future success is significantly dependent on the timely and successful development and commercialization of BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease; if we encounter delays or difficulties in the development of this product candidate, as well as any other product candidates, our business prospects would be significantly harmed.
  • We may experience delays and other difficulties in enrolling a sufficient number of patients in our clinical trials which could delay or prevent the receipt of necessary regulatory approvals.
  • We may have other delays in completing our clinical trials and we may not complete them at all.
  • The development of our cell therapy product candidates is subject to uncertainty because autologous cell therapy is inherently variable.
  • Any disruption to our access to the media (including cell culture media) and reagents we are using in the clinical development of our cell therapy product candidates could adversely affect our ability to perform clinical trials and seek future regulatory submissions.
  • Products that appear promising in research and development may be delayed or may fail to reach later stages of clinical development.
  • Our clinical trials may fail to demonstrate adequately the safety and efficacy of our product candidates, which would prevent or delay regulatory approval and commercialization.
  • Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate, and the approval may be for a narrower indication than we seek.
  • We may never obtain FDA approval for any of our product candidates in the United States and, even if we do, we may never obtain approval for or commercialize any of our product candidates in any foreign jurisdiction, which would limit our ability to realize our full market potential.
  • We presently lack manufacturing capabilities to produce our product candidates at commercial scale quantities and do not have an alternate manufacturing supply at this time, which could negatively impact our ability to meet any future demand for the products.
  • The commercial potential and profitability of our products are unknown and subject to significant risk and uncertainty.
  • We may have difficulties in sourcing brown adipose (fat) tissue.
  • If safety problems are encountered by us or others developing new stem cell-based therapies, our stem cell initiatives could be materially and adversely affected.
  • We are vulnerable to competition and technological change, and also to physicians’ inertia.
  • We may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
  • We have limited experience in the development and marketing of cell therapies and may be unsuccessful in our efforts to establish a profitable business.
  • Our cell therapy business is based on novel technologies that are inherently expensive, risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value.
  • Our cell therapy product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.
  • The FDA’s regulation of regenerative medicine products remains unpredictable and we are not certain what impact this will have on the potential approval of our products.
  • We may be subject to significant product liability claims and litigation, including potential exposure from the use of our product candidates in human subjects, and our insurance may be inadequate to cover claims that may arise.
  • Our internal computer systems, or those that are expected to be used by our clinical investigators, clinical research organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of development programs for our product candidates.
  • To operate and sell in international markets carries great risk.
  • Our inability to obtain reimbursement for our products and services from private and governmental insurers could negatively impact demand for our products and services.
  • Our activity as a contract manufacturer of biologic-based cosmetics could result in FDA enforcement for reasons outside of our control, which could disrupt the development of our own product candidates or harm our reputation.
  • We may not be able to protect our proprietary rights.
  • We may not be able to protect our intellectual property in countries outside of the United States.
  • Changes to United States patent law may have a material adverse effect on our intellectual property rights.
  • In certain countries, patent holders may be required to grant compulsory licenses, which would likely have a significant and detrimental effect on any future revenues in such country.
  • Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.
  • We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
  • Our current and future employees, consultants and advisors and our future principal investigators, medical institutions and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • The failure to receive regulatory approvals for our cell therapy product candidates would likely have a material and adverse effect on our business and prospects.
  • If we are unable to conduct clinical studies in accordance with regulations and accepted standards, we may be delayed in receiving, or may never receive, regulatory approvals of our product candidates from the FDA and other regulatory authorities.
  • Health care companies have been the subjects of federal and state investigations, and we could become subject to investigations in the future.
  • It is uncertain to what extent the government, private health insurers and third-party payors will approve coverage or provide reimbursement for the therapies and products to which our services relate. Availability for such reimbursement may be further limited by reductions in Medicare, Medicaid and other federal healthcare program funding in the United States.
  • Unintended consequences of healthcare reform in the United States may adversely affect our business.
  • Competitor companies or hospitals in the EU may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients to sell competing products without a marketing authorization.
  • We pay no dividends.
  • There is no assurance that an active trading market for our common stock will be sustained.
  • Stockholders who hold unregistered shares of our common stock are subject to resale restrictions pursuant to Rule 144 due to our former status as a “shell company.”
  • We have incurred, and will continue to incur, increased costs as a result of being an SEC reporting company.
  • Material weaknesses in our internal control over financial reporting have caused and may cause us to fail to timely and accurately report our financial results or result in a material misstatement of our consolidated financial statements.
  • Our stock price may fluctuate significantly and be highly volatile and this may make it difficult for a securityholder to resell our securities at the volume, prices and times the securityholder finds attractive.
  • There may be significant future issuances or resales of our common stock which may materially and adversely dilute stockholders’ ownership interest and affect the market price of our securities.
  • Our common stock is classified as a “penny stock;” the restrictions of the penny stock regulations of the SEC may result in less liquidity for our common stock.
  • Anti-takeover provisions and the regulations to which we may be subject may make it more difficult for a third party to acquire control of us, even if the change in control would be beneficial to our securityholders.
  • We cannot assure you that we will be able to comply with the minimum bid price requirement of Nasdaq.
  • The market price of our common stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our common stock may not improve.
  • Our failure to meet the continued listing standards of Nasdaq could result in a delisting of our common stock.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59